Key Highlights
- ACET shares dropped 29.60% to $6.35 at Monday's close on September 28, 2026, as the Dow lost 0.67%.
- Adicet held a webcast on September 28 to present Phase 1 data for prula-cel in systemic lupus erythematosus.
- Prula-cel, formerly ADI-001, is an allogeneic, off-the-shelf CAR T-cell candidate framed as moving toward a pivotal lupus trial.
- Adicet is a clinical-stage biotechnology company focused on cell therapy, with autoimmune disease as its central area of development.
On Monday, September 28, 2026, Adicet Bio (NASDAQ:ACET) dropped 29.60% to finish at $6.35. The clinical-stage biotech held a webcast on the same day to present Phase 1 data for its lead candidate in lupus.
Latest Developments
Adicet held a webcast on September 28, 2026 to present Phase 1 clinical data for prula-cel (prulacabtagene leucel, formerly ADI-001) in patients with systemic lupus erythematosus, with or without lupus nephritis.
The company has been advancing the program in autoimmune disease and has framed prula-cel as moving toward a pivotal lupus trial, so the early clinical results carried real significance for the candidate's path forward.
Financial and Business Position
Adicet Bio is a clinical-stage biotechnology company focused on cell therapy, best known for developing allogeneic, off-the-shelf CAR T-cell candidates. Its lead program targets autoimmune disease, with lupus as a central indication.
Stock-Market Context
Stocks closed the first session of the week in the red, with the S&P 500 at 7,683.69, off 0.77%, the Dow at 51,481.51, off 0.67%, and the Nasdaq Composite at 26,820.38, off 0.92%. The Russell 2000 gave up 0.69%.
Rates and energy set the macro backdrop: the 10-year Treasury Yield rose above 5.2%, the highest reading since 2007, and WTI crude touched about $96 a barrel intraday amid stalled US-Iran negotiations.
Clinical-stage biotechs are sensitive to rising yields because their value depends on cash flows expected years out.
Early Lupus Data Meet the Pivotal-Trial Plan
Adicet closed Monday sharply lower on the day it presented Phase 1 lupus data for prula-cel. The candidate's path toward a pivotal trial remains the central question for the company, and the data presented on September 28 are the newest input to that question.






Please wait processing your request...